Genitourinary Syndrome of Menopause (GSM)

In recent years, vulvovaginal atrophy (VVA) or atrophic vaginitis has a new name: Genitourinary Syndrome of Menopause (GSM).

Genitourinary Syndrome of Menopause

Where did the new terminology come from?

The term Genitourinary Syndrome of Menopause was introduced as a more comprehensive and acceptable descriptor, including both genital and urinary symptoms associated with menopause.

This new terminology aims to improve understanding, communication, and treatment of the condition among healthcare providers, patients, and the public.

The International Society for the Study of Women’s Sexual Health (ISSWSH) and the North American Menopause Society (NAMS) held a consensus conference with experts to review the literature and select a more comprehensive term.

Overall, GSM was ultimately chosen, as it includes both genital and urinary symptoms and is expected to improve clarity, acceptance, and dialogue among healthcare providers, patients, and the public.

This change aims to foster a better understanding of menopausal health, enhancing diagnosis, treatment, and quality of life for affected women.

Portman, D.J. and Gass, M.L., 2014. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. The journal of sexual medicine, 11(12), pp.2865-2872.

Disclaimer: This product is currently under development and has not been approved for sale by the U.S. Food and Drug Administration (FDA) or under the EU Medical Device Regulation (MDR). It is not available for purchase in the United States or the European Union.